Protagenic Therapeutics reports zero clinically-relevant adverse events in Phase 1 single dose portion for PT00114

Protagenic Therapeutics, Inc.new

Phase 1 single dose trial completed with 30 subjects across five cohorts up to 1,000 micrograms; no clinically-relevant adverse events.
Multiple ascending dose portion of the trial is planned to commence later this year.
PT00114 targets stress reduction as root cause for PTSD, depression, anxiety, addiction, and potentially obesity.
Investor call scheduled for May 22 at 10:00 am ET to discuss safety data and implications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.